ArticleFrontiers in public health2022
Interaction between physicians and the pharmaceutical industry: A scoping review for developing a policy brief.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Causes of medication errors in community pharmacies: A meta-ethnography and systematic review.PloS one · 2026Pooled it
- Associations between pharmaceutical industry interactions with physicians and chronic nonmalignant pain management prescribing practices: a systematic review.Cost effectiveness and resource allocation : C/E · 2026Review
- The use of generic versus brand names in (clinical) pharmacology education across Europe: a cross-sectional survey.European journal of clinical pharmacology · 2026Article
- Contesting the C Word: The Diagnosis of DCIS and Women's Resistance Against Overtreatment.Sociology of health & illness · 2026Article
- Assessment of bioethics education, ethical awareness, and training needs among physicians in Jordan.Global bioethics = Problemi di bioetica · 2026Article
- Pharmaceutical marketing and patient trust: How do doctor-targeted campaigns affect patients?PloS one · 2026Article
- Perceptions and experiences of community pharmacists about weight loss dietary supplements: a qualitative study.Journal of pharmaceutical health care and sciences · 2025Article
- Patterns of Prescription Switching in a Uniform-Pricing System for Multi-Source Drugs: A Retrospective Population-Based Cohort Study.Healthcare (Basel, Switzerland) · 2025Article
- National trends in Azithromycin consumption during 2017-2023 in Kazakhstan: impact of the COVID-19 pandemic and the imperative for enhanced clinical guidelines.Scientific reports · 2025Article
- Ask a Doctor a Question: A Clinician's Message to the Industry.Medicina (Kaunas, Lithuania) · 2025Article
- Eligibility and Accessibility Barriers of Patient Assistance Programs for Oral Oncolytics in Patients With Cancer.Clinical journal of oncology nursing · 2025Review
- Ethical challenges in contemporary psychiatry: an overview and an appraisal of possible strategies and research needs.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2024Article
- The Primacy of Ethics in Aesthetic Medicine: A Review.Plastic and reconstructive surgery. Global open · 2024Article
- Article
- Article
- Attitudes of ophthalmologists towards pharmaceutical promotion.La Tunisie medicaleArticle
- Prescribing equity: physicians as advocates for access to essential medicines. A call to action from medical graduates.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Payments to physicians by the pharmaceutical industry are common, but recent evidence shows that these payments influence physician prescribing behavior in the form of increased prescription of brand-name drugs, expensive and low-cost drugs, increased prescription of payer company drugs, etc. Considering that these payments increase drug costs for patients and health systems, there is a public interest in controlling them. Therefore, this study aimed to identify and propose policy options for managing physician-pharmaceutical industry interactions in the context of Iran's health system. Methods: In the first phase, a systematic search was conducted to identify relevant policies and interventions in Web of Science, PubMed, and ProQuest databases from 2000 to 2022. Then, the opinions of the research team and an expert group (physicians, health policy and transparency experts, and industry representatives) were used to categorize the interventions and propose policy options along with their advantages, disadvantages, and implementation considerations. Results: In the search, 579 articles were retrieved, and 44 articles were found suitable for the final analysis. Twenty-nine interventions and strategies were identified, and based on these; Five policy options were identified: prohibition, restriction, physician self-regulation, voluntary industry disclosure, and mandatory industry disclosure. Conclusion: The proposed policies in our study include advantages, challenges, and implementation considerations based on up-to-date evidence that can help policymakers use them to manage COI in physician-pharmaceutical industry interactions in Iran's health system. A combination of measures seems to help manage COI: firstly, using self-regulating physicians and industry to institutionalize transparency, and in the next step, implementing mandatory industry disclosure policies and establishing restrictions on some financial interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.